Reassurance against future risk of precancer and cancer conferred by a negative human papillomavirus test

Journal of the National Cancer Institute

Volumn 106, Issue 8, 2014, Pages

  Gage, Julia C ^a   Schiffman, Mark ^a   Katki, Hormuzd A ^a   Castle, Philip E ^b   Fetterman, Barbara ^c   Wentzensen, Nicolas ^a   Poitras, Nancy E ^c   Lorey, Thomas ^c   Cheung, Li C ^d   Kinney, Walter K ^c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Global Cancer Initiative   (United States)

^c KAISER PERMANENTE   (United States)

^d INFORMATION MANAGEMENT SERVICES INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER RISK; CANCER SCREENING; COLPOSCOPY; FEMALE; FOLLOW UP; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; MAJOR CLINICAL STUDY; NONHUMAN; PAPANICOLAOU TEST; PRACTICE GUIDELINE; PRECANCER; PREDICTIVE VALUE; PRIORITY JOURNAL; REASSURANCE; STATISTICAL SIGNIFICANCE; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; COHORT ANALYSIS; EARLY DIAGNOSIS; EPIDEMIOLOGY; INCIDENCE; ISOLATION AND PURIFICATION; MASS SCREENING; METHODOLOGY; MIDDLE AGED; PAPILLOMA VIRUS; PAPILLOMAVIRUS INFECTION; PROGRAM EVALUATION; RISK ASSESSMENT; TIME; UNITED STATES; UTERINE CERVIX TUMOR; VAGINA SMEAR; VIROLOGY;

ADULT; CALIFORNIA; CERVICAL INTRAEPITHELIAL NEOPLASIA; COHORT STUDIES; CONFOUNDING FACTORS (EPIDEMIOLOGY); EARLY DETECTION OF CANCER; FEMALE; HUMANS; INCIDENCE; MASS SCREENING; MIDDLE AGED; PAPANICOLAOU TEST; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PRECANCEROUS CONDITIONS; PREDICTIVE VALUE OF TESTS; PROGRAM EVALUATION; RISK ASSESSMENT; TIME FACTORS; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 84930742769     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dju153     Document Type: Article

References (14)

1. Ronco G, Dillner J, Elfstrom KM, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet. 2014;383(9916):524-532.
2. Sankaranarayanan R, Nene BM, Shastri SS, et al. HPV screening for cervical cancer in rural India. N Engl J Med. 2009;360(14):1385-1394.
3. Saslow D, Solomon D, Lawson HW, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. J Low Genit Tract Dis. 2012;16(3):175-204.
4. ACOG Practice Bulletin Number 131: Screening for cervical cancer. Obstet Gynecol. 2012;120(5):1222-1238.
5. Moyer VA. Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;156(12):880-891, W312.
6. Katki HA, Kinney WK, Fetterman B, et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol. 2011;12(7):663-672.
7. Massad LS, Einstein MH, Huh WK, et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis. 2013;17(5 Suppl 1):S1-S27.
8. Katki HA, Schiffman M, Castle PE, et al. Benchmarking CIN 3+ risk as the basis for incorporating HPV and Pap cotesting into cervical screening and management guidelines. J Low Genit Tract Dis. 2013;17(5 Suppl 1):S28-S35.
9. Katki HA, Schiffman M, Castle PE, et al. Five-year risks of CIN 3+ and cervical cancer among women who test Pap-negative but are HPV-positive. J Low Genit Tract Dis. 2013;17(5 Suppl 1):S56-S63.
10. Katki HA, Schiffman M, Castle PE, et al. Five-year risks of CIN 2+ and CIN 3+ among women with HPV-positive and HPV-negative LSIL Pap results. J Low Genit Tract Dis 2013;17(5 Suppl 1):S43-9.
11. Cox JT, Castle PE, Behrens CM, et al. Comparison of cervical cancer screening strategies incorporating different combinations of cytology, HPV testing, and genotyping for HPV 16/18: results from the ATHENA HPV study. Am J Obstet Gynecol. 2013;208(3):184 e1-184 e11.
12. Dillner J, Rebolj M, Birembaut P, et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ. 2008;337:a1754.
13. Zhao FH, Lin MJ, Chen F, et al. Performance of high-risk human papillomavirus DNA testing as a primary screen for cervical cancer: a pooled analysis of individual patient data from 17 population-based studies from China. Lancet Oncol. 2010;11(12):1160-1171.
14. Netherlands HCot. Population screening for cervical cancer. In: The Hague: Health Council of the Netherlands; 2011.